Ideaya Biosciences (IDYA.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Dec12

GSK to Terminate Collaboration and License Agreement with IDEAYA Biosciences

21:37

Citi Analyst Maintains Buy Rating on Ideaya Biosciences

15:57

Dec11

IDEAYA Biosciences Completes Patient Enrollment for darovasertib and crizotinib Therapy Clinical Trial in Metastatic Uveal Melanoma

11:01

Dec10

IDEAYA Biosciences Inc Submits IDE574 IND and Plans First Phase Trial

11:02

Dec5

IDEAYA Biosciences and Biocytogen Pharmaceuticals Obtain FDA Approval for IDE034 IND Application

00:00

Nov12

Mizuho Raises IDEAYA Biosciences Price Target to $46

14:29

Schedules & Filings

Schedules

Filings

Nov4

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 207.83 M, Net Income 119.24 M, EPS 1.33

Aug5

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -77.49 M, EPS -0.8758

May6

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -72.18 M, EPS -0.8168

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change